Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Intellia Therapeutics to Present at ASH

Intellia Therapeutics (NTLA) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, GA, as well as virtually, December 11-14, 2021.

From the CSO at Intellia Therapeutics

Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics, said, “As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting. The data will feature our novel allogeneic technology designed to overcome rejection by host T and NK cells without the need for host immune suppression, as well as highlight our clinical-scale manufacturing process developed for NTLA-5001, our TCR-based T cell therapeutic candidate for the treatment of acute myeloid leukemia. Together, the data support our progress toward developing engineered cell therapies with the potential to transform the lives of people living with life-threatening diseases.”

Leave a Reply